Please assess the completion status of the following clinical trial:

Trial Title: Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatient veterans.~* Current DSM-IV diagnosis of PTSD.~* Current (past month) DSM-IV diagnosis of an Alcohol Use Disorder.~* Must meet criteria for heavy or at-risk drinking by NIAAA thresholds.~* Receiving treatment for PTSD.~* Must express desire to reduce alcohol consumption.~* Female subjects must have negative urine pregnancy test and must be either postmenopausal for at least one year, or practicing an effective method of birth control.~* Must have a BAC of less than 0.02% when signing the informed consent.~Exclusion Criteria:~* Psychotic disorders, bipolar disorder, dementia, or other psychiatric disorders judged to be unstable.~* Subjects known to have clinically significant unstable medical conditions, including but not limited to: clinically significant renal disease and/or impaired renal function as defined by clinically significant elevation of BUN or creatinine or an estimated creatinine clearance of \< 60 mL/min; AST (SGOT) and/or ALT (SGPT) \>3 times the upper limit of the normal range and/or an increased serum bilirubin \>2 times the upper limit of normal; seizure disorders.~* Subjects with glaucoma.~* Subjects with a history of kidney stones.~* Subjects with a history of renal disease.~* Concurrent participation in another treatment study.~* Female patients who are pregnant or lactating.~* Current topiramate use or use within the past 4 weeks.~* Current medications for alcohol dependence or use within the past 4 weeks.~* Needing acute medical detoxification from alcohol based on a score of 12 or more on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD);~* Subjects who are legally mandated to participate in an alcohol treatment program.~* Subjects who have had a suicide attempt or suicidal ideation in the 6 months prior to enrollment.~* Subjects who have previously been treated with topiramate for any reason and discontinued treatment due to an adverse event or due to a hypersensitivity reaction to topiramate,~* Subjects with seizure disorders that require anticonvulsant medications~* Subjects currently being treated with another anticonvulsant.~* Subjects who in the opinion of the investigator should not be enrolled in the study because of the precautions,warnings or contraindications outlined in the topiramate package insert.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Topiramate (Type: EXPERIMENTAL): Participants will be randomly assigned to either the topiramate arm or placebo arm. Neither the participant nor the researchers will know which arm the participant is in. Participants in the topiramate arm will be ingesting daily doses of topiramate that will gradually increase to a maximum, and then taper off.
- Placebo (Type: PLACEBO_COMPARATOR): The Drug Product Services Laboratory at UCSF will purchase and supply our lab with USP or NF grade topiramate study capsules and matching placebo capsules. Randomization will be done by a consulting biostatistician, who will be the only one to know which participants are assigned to placebo. Dosing will follow the same procedures as with topiramate in that arm of the study. If adverse events occur, there will be a procedure in place for unblinding only that participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).